CJC-1295 vs Ipamorelin | Research Comparison

CJC-1295 No DAC and Ipamorelin are two of the most widely used growth hormone secretagogues in laboratory research. While both stimulate GH release, they act on entirely different receptors and through distinct mechanisms — making them complementary rather than interchangeable tool compounds. This page provides a structured comparison for researchers selecting between or combining these peptides in experimental designs.

At a Glance

Property	CJC-1295 No DAC	Ipamorelin
Receptor target	GHRH receptor (GHRHR)	Ghrelin receptor (GHS-R1a)
Peptide class	GHRH analogue (29 AA)	GH secretagogue pentapeptide
Mechanism	Stimulates GH synthesis and pulsatile release via GHRHR	Stimulates GH release via GHS-R1a activation
Selectivity	GHRHR-selective	Highly selective for GHS-R1a; minimal cortisol/prolactin effect
GH pulse pattern	Amplifies natural GH pulses	Stimulates discrete GH pulses
Molecular weight	~3368 Da	~711 Da
Stability	DPP-IV resistant via amino acid substitutions	Resistant to proteolysis via non-natural amino acids
Combined use	Synergistic — dual receptor activation produces additive GH release

Mechanism of Action

CJC-1295 No DAC

CJC-1295 No DAC (Modified GRF 1-29) binds to GHRH receptors on pituitary somatotroph cells, stimulating GH synthesis and pulsatile secretion. Its four stabilising amino acid substitutions confer resistance to DPP-IV degradation while preserving GHRHR binding affinity. In laboratory models, it produces GH pulses that closely mimic endogenous pulsatile GH secretion patterns.

Ipamorelin

Ipamorelin binds to GHS-R1a (ghrelin receptor) on somatotroph cells, stimulating GH release through a cAMP/PKA and IP3/PKC-dependent pathway distinct from GHRHR signalling. Its high receptor selectivity means it does not significantly stimulate ACTH, cortisol or prolactin in laboratory models, making it a precise tool for isolating GHS-R-mediated GH release.

Combined Use in Research

CJC-1295 and Ipamorelin are frequently used together in laboratory research because they act on complementary receptors. GHRHR and GHS-R1a activation are synergistic — combined stimulation produces GH release that exceeds either compound alone. This combination is used to study receptor crosstalk, cooperative somatotroph stimulation and the additive effects of dual GH secretagogue pathways in experimental models.

Solatide Biosciences supplies CJC-1295 No DAC and Ipamorelin as a combined research material (10mg total, 5mg each).

Key Research Differences

Receptor Pathway

The most fundamental difference is receptor target. CJC-1295 activates GHRHR — the primary receptor for endogenous GHRH — while Ipamorelin activates GHS-R1a, the ghrelin receptor. These are distinct signalling pathways that can be studied independently or in combination depending on the experimental question.

Selectivity Profile

Ipamorelin is notable for its high selectivity — it does not significantly stimulate cortisol, ACTH or prolactin in laboratory models at research concentrations. CJC-1295 is GHRHR-selective but its downstream effects are broader due to the central role of GH in metabolic regulation. For experiments requiring isolated GHS-R activation without confounding hormonal effects, Ipamorelin is the more selective tool.

GH Pulse Dynamics

CJC-1295 No DAC amplifies existing GH pulses and is preferred in laboratory models studying physiological pulsatile GH secretion. Ipamorelin stimulates discrete GH pulses independently of the endogenous GHRH cycle. Combined, they produce robust GH release suitable for studying the full GH secretagogue response.

Choosing Between Them for Research

The choice depends on the experimental question. For studying GHRHR signalling specifically, CJC-1295 is the appropriate tool. For studying GHS-R1a pharmacology and ghrelin receptor biology, Ipamorelin is preferred. For studying combined or synergistic GH secretagogue effects, both are used together. Most laboratory research protocols studying GH axis activation use the combination.

Related Resources

---